Maxpro News Maxpro Capital Acquisition Corp. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option Posted on 2021-10-132021-11-03 by maxproadmin More >>
Arthrosi Arthrosi Appoints Robert Thomas Keenan MD, MPH, MBA as Chief Medical Officer Posted on 2021-10-122021-11-03 by maxproadmin More >>
Maxpro News Maxpro Capital Acquisition Corp. Announces Pricing of $90,000,000 Initial Public Offering Posted on 2021-10-072021-11-03 by maxproadmin More >>
ACT Genomics CerbACT Asia Holds Ribbon Cutting to Celebrate New Immuno-oncology Centre of Excellence Posted on 2021-10-072021-11-03 by maxproadmin More >>
Acepodia Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors Posted on 2021-09-162021-11-03 by maxproadmin More >>
Acepodia Acepodia to Present Data from Preclinical and Phase 1 Studies of ACE1702 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress Posted on 2021-09-132021-11-03 by maxproadmin More >>
ACT Genomics Cerba Research and ACT Genomics announce strategic Joint Venture – CerbACT Asia Posted on 2021-08-252021-11-03 by maxproadmin More >>
Arthrosi Arthrosi Establishes Joint Venture in China to Accelerate Development of Innovative Drug Portfolio Posted on 2021-08-172021-12-03 by maxproadmin More >>
Maxpro News SPAC Jade Mountain Acquisition files for a $100 million IPO, targeting health and tech Posted on 2021-07-222021-07-27 by maxproadmin More >>
EirGenix EIRGENIX ACHIEVES THE FOURTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT Posted on 2021-07-212021-11-03 by maxproadmin More >>